Tami John is an Oncology physician affiliated with California Institute for Regenerative Medicine. OpenAlex indexes 71 publications with 356 citations (h-index 11); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
725 Welch Rd
Palo Alto, CA 943041601
Telephone
650-497-8000Provider last certified this registry record 16 Apr 2024.
Clinical trials
- Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP
Sponsor: Tami D. John
- Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO
Sponsor: Baylor College of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year20259 payments$12,491openpaymentsdata.cms.gov ↗
- Genetix Biotherapeutics IncProgram year20259 payments
- National Marrow Donor ProgramProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Outcomes Following Graft Failure and Second Subsequent Allogeneic Hematopoietic Cell Transplant in Patients with Sickle Cell Disease: A Multicenter Study
Biology of Blood and Marrow Transplantation
2026 - Long-Term Cardiac Function Remains Stable to Improved Following Curative Allogeneic Hematopoietic Cell Transplantation for Pediatric Sickle Cell Disease: A STAR Analysis
Biology of Blood and Marrow Transplantation
2026 - G‐ <scp>CSF</scp> for Mobilizing <scp> CD34 <sup>+</sup> </scp> Cells in Individuals With <scp>SCD</scp> : A Word of Caution
American Journal of Hematology
2026 - Model-Based ATG Dosing Optimization in Αβ Haplo-HSCT: Improved Pre-HSCT Exposure Consistency and Viral Infection Analysis
Biology of Blood and Marrow Transplantation
2026
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”